US FDA Questions Adequacy Of Mesoblast’s Remestemcel-L Single-Arm Study For Pediatric GVHD

 
• By Brenda Sandburg
  
Stem Cells Therapy Concept stem cell transplant through perfusion
FDA panel to vote on whether data support efficacy of remestemcel-L in pediatric patients with graft-versus-host disease • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers